Differentiation of NUT midline carcinoma by epigenomic reprogramming

Brian E. Schwartz, Matthias D. Hofer, Madeleine E. Lemieux, Daniel E. Bauer, Michael J. Cameron, Nathan H. West, Elin S. Agoston, Nicolas Reynoird, Saadi Khochbin, Tan Ince, Amanda Christie, Katherine A. Janeway, Sara O. Vargas, Antonio R. Perez-Atayde, Jon C. Aster, Stephen E. Sallan, Andrew L. Kung, James E. Bradner, Christopher A. French

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

NUT midline carcinoma (NMC) is a lethal pediatric tumor defined by the presence of BRD-NUT fusion proteins that arrest differentiation. Here we explore the mechanisms underlying the ability of BRD4-NUT to prevent squamous differentiation. In both gain-of and loss-of-expression assays, we find that expression of BRD4-NUT is associated with globally decreased histone acetylation and transcriptional repression. Bulk chromatin acetylation can be restored by treatment of NMC cells with histone deacetylase inhibitors (HDACi), engaging a program of squamous differentiation and arrested growth in vitro that closely mimics the effects of siRNA-mediated attenuation of BRD4-NUT expression. The potential therapeutic utility of HDACi differentiation therapy was established in three different NMC xenograft models, where it produced significant growth inhibition and a survival benefit. Based on these results and translational studies performed with patientderived primary tumor cells, a child with NMC was treated with the FDA-approved HDAC inhibitor, vorinostat. An objective response was obtained after five weeks of therapy, as determined by positron emission tomography. These findings provide preclinical support for trials of HDACi in patients with NMC.

Original languageEnglish
Pages (from-to)2686-2696
Number of pages11
JournalCancer Research
Volume71
Issue number7
DOIs
StatePublished - Apr 1 2011
Externally publishedYes

Fingerprint

Epigenomics
Histone Deacetylase Inhibitors
Carcinoma
Acetylation
Therapeutics
Growth
Heterografts
Positron-Emission Tomography
Histones
Small Interfering RNA
Chromatin
Neoplasms
Pediatrics
Survival
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Schwartz, B. E., Hofer, M. D., Lemieux, M. E., Bauer, D. E., Cameron, M. J., West, N. H., ... French, C. A. (2011). Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Research, 71(7), 2686-2696. https://doi.org/10.1158/0008-5472.CAN-10-3513

Differentiation of NUT midline carcinoma by epigenomic reprogramming. / Schwartz, Brian E.; Hofer, Matthias D.; Lemieux, Madeleine E.; Bauer, Daniel E.; Cameron, Michael J.; West, Nathan H.; Agoston, Elin S.; Reynoird, Nicolas; Khochbin, Saadi; Ince, Tan; Christie, Amanda; Janeway, Katherine A.; Vargas, Sara O.; Perez-Atayde, Antonio R.; Aster, Jon C.; Sallan, Stephen E.; Kung, Andrew L.; Bradner, James E.; French, Christopher A.

In: Cancer Research, Vol. 71, No. 7, 01.04.2011, p. 2686-2696.

Research output: Contribution to journalArticle

Schwartz, BE, Hofer, MD, Lemieux, ME, Bauer, DE, Cameron, MJ, West, NH, Agoston, ES, Reynoird, N, Khochbin, S, Ince, T, Christie, A, Janeway, KA, Vargas, SO, Perez-Atayde, AR, Aster, JC, Sallan, SE, Kung, AL, Bradner, JE & French, CA 2011, 'Differentiation of NUT midline carcinoma by epigenomic reprogramming', Cancer Research, vol. 71, no. 7, pp. 2686-2696. https://doi.org/10.1158/0008-5472.CAN-10-3513
Schwartz BE, Hofer MD, Lemieux ME, Bauer DE, Cameron MJ, West NH et al. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Research. 2011 Apr 1;71(7):2686-2696. https://doi.org/10.1158/0008-5472.CAN-10-3513
Schwartz, Brian E. ; Hofer, Matthias D. ; Lemieux, Madeleine E. ; Bauer, Daniel E. ; Cameron, Michael J. ; West, Nathan H. ; Agoston, Elin S. ; Reynoird, Nicolas ; Khochbin, Saadi ; Ince, Tan ; Christie, Amanda ; Janeway, Katherine A. ; Vargas, Sara O. ; Perez-Atayde, Antonio R. ; Aster, Jon C. ; Sallan, Stephen E. ; Kung, Andrew L. ; Bradner, James E. ; French, Christopher A. / Differentiation of NUT midline carcinoma by epigenomic reprogramming. In: Cancer Research. 2011 ; Vol. 71, No. 7. pp. 2686-2696.
@article{6a5c65ed41984ebfb36a354b6109e289,
title = "Differentiation of NUT midline carcinoma by epigenomic reprogramming",
abstract = "NUT midline carcinoma (NMC) is a lethal pediatric tumor defined by the presence of BRD-NUT fusion proteins that arrest differentiation. Here we explore the mechanisms underlying the ability of BRD4-NUT to prevent squamous differentiation. In both gain-of and loss-of-expression assays, we find that expression of BRD4-NUT is associated with globally decreased histone acetylation and transcriptional repression. Bulk chromatin acetylation can be restored by treatment of NMC cells with histone deacetylase inhibitors (HDACi), engaging a program of squamous differentiation and arrested growth in vitro that closely mimics the effects of siRNA-mediated attenuation of BRD4-NUT expression. The potential therapeutic utility of HDACi differentiation therapy was established in three different NMC xenograft models, where it produced significant growth inhibition and a survival benefit. Based on these results and translational studies performed with patientderived primary tumor cells, a child with NMC was treated with the FDA-approved HDAC inhibitor, vorinostat. An objective response was obtained after five weeks of therapy, as determined by positron emission tomography. These findings provide preclinical support for trials of HDACi in patients with NMC.",
author = "Schwartz, {Brian E.} and Hofer, {Matthias D.} and Lemieux, {Madeleine E.} and Bauer, {Daniel E.} and Cameron, {Michael J.} and West, {Nathan H.} and Agoston, {Elin S.} and Nicolas Reynoird and Saadi Khochbin and Tan Ince and Amanda Christie and Janeway, {Katherine A.} and Vargas, {Sara O.} and Perez-Atayde, {Antonio R.} and Aster, {Jon C.} and Sallan, {Stephen E.} and Kung, {Andrew L.} and Bradner, {James E.} and French, {Christopher A.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-10-3513",
language = "English",
volume = "71",
pages = "2686--2696",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Differentiation of NUT midline carcinoma by epigenomic reprogramming

AU - Schwartz, Brian E.

AU - Hofer, Matthias D.

AU - Lemieux, Madeleine E.

AU - Bauer, Daniel E.

AU - Cameron, Michael J.

AU - West, Nathan H.

AU - Agoston, Elin S.

AU - Reynoird, Nicolas

AU - Khochbin, Saadi

AU - Ince, Tan

AU - Christie, Amanda

AU - Janeway, Katherine A.

AU - Vargas, Sara O.

AU - Perez-Atayde, Antonio R.

AU - Aster, Jon C.

AU - Sallan, Stephen E.

AU - Kung, Andrew L.

AU - Bradner, James E.

AU - French, Christopher A.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - NUT midline carcinoma (NMC) is a lethal pediatric tumor defined by the presence of BRD-NUT fusion proteins that arrest differentiation. Here we explore the mechanisms underlying the ability of BRD4-NUT to prevent squamous differentiation. In both gain-of and loss-of-expression assays, we find that expression of BRD4-NUT is associated with globally decreased histone acetylation and transcriptional repression. Bulk chromatin acetylation can be restored by treatment of NMC cells with histone deacetylase inhibitors (HDACi), engaging a program of squamous differentiation and arrested growth in vitro that closely mimics the effects of siRNA-mediated attenuation of BRD4-NUT expression. The potential therapeutic utility of HDACi differentiation therapy was established in three different NMC xenograft models, where it produced significant growth inhibition and a survival benefit. Based on these results and translational studies performed with patientderived primary tumor cells, a child with NMC was treated with the FDA-approved HDAC inhibitor, vorinostat. An objective response was obtained after five weeks of therapy, as determined by positron emission tomography. These findings provide preclinical support for trials of HDACi in patients with NMC.

AB - NUT midline carcinoma (NMC) is a lethal pediatric tumor defined by the presence of BRD-NUT fusion proteins that arrest differentiation. Here we explore the mechanisms underlying the ability of BRD4-NUT to prevent squamous differentiation. In both gain-of and loss-of-expression assays, we find that expression of BRD4-NUT is associated with globally decreased histone acetylation and transcriptional repression. Bulk chromatin acetylation can be restored by treatment of NMC cells with histone deacetylase inhibitors (HDACi), engaging a program of squamous differentiation and arrested growth in vitro that closely mimics the effects of siRNA-mediated attenuation of BRD4-NUT expression. The potential therapeutic utility of HDACi differentiation therapy was established in three different NMC xenograft models, where it produced significant growth inhibition and a survival benefit. Based on these results and translational studies performed with patientderived primary tumor cells, a child with NMC was treated with the FDA-approved HDAC inhibitor, vorinostat. An objective response was obtained after five weeks of therapy, as determined by positron emission tomography. These findings provide preclinical support for trials of HDACi in patients with NMC.

UR - http://www.scopus.com/inward/record.url?scp=79953320005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953320005&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-3513

DO - 10.1158/0008-5472.CAN-10-3513

M3 - Article

VL - 71

SP - 2686

EP - 2696

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -